Cantor Fitzgerald Reiterates Neutral Rating on Merck (MRK)

Cantor Fitzgerald analyst Carter Gould reiterated a Neutral rating and $85.00 price target on Merck (NYSE: MRK).

The analyst commented, “There was already uncertainty and worry that the prior ACIP members would recommend a 1-2 dose regimen of Gardasil, potentially putting pressure on Gardasil U.S. sales estimates. We’ve written before that while we thought momentum was clearly heading in that direction (though we thought the risk to ’25 sales was exaggerated given current usage patterns, entrenched clinician behaviors, and potential pricing action Merck could take). We view the new uncertainty around ACIP of cutting both ways now – potentially pushing out an unfavorable decision for Merck until the October meeting or incrementally raising the probability of support for a 1-2 dose regimen at the June meeting.”

For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.

Shares of Merck closed at $79.33 yesterday.

You May Also Be Interested In

• Merck (MRK) PT Raised to $142 at BMO Capital
• Honeywell Aerospace launches $16B note exchange offer
• Diamondrock Hospitality (DRH) PT Raised to $12.50 at Stifel